LPCAT2 inhibitors belong to a specialized class of chemical compounds that have garnered attention in the field of lipid metabolism and membrane biogenesis research. LPCAT2, or Lysophosphatidylcholine Acyltransferase 2, is an enzyme that plays a pivotal role in the biosynthesis of phospholipids, essential components of cell membranes. The term LPCAT2 inhibitors refers to a group of molecules meticulously designed to selectively target and modulate the activity of LPCAT2. These inhibitors serve as invaluable tools in laboratory investigations, enabling researchers to explore the intricate molecular functions and cellular processes associated with LPCAT2.
LPCAT2 inhibitors typically function by interfering with the enzymatic activity of LPCAT2, thereby disrupting the conversion of lysophosphatidylcholine (LPC) to phosphatidylcholine (PC), an essential step in membrane phospholipid biosynthesis. This interference can lead to alterations in membrane composition, affecting various aspects of cellular membrane structure and function. Researchers employ LPCAT2 inhibitors to gain insights into the physiological roles and molecular interactions of LPCAT2 within cells, aiming to advance our understanding of the fundamental mechanisms involved in membrane biogenesis and lipid metabolism. Through the study of LPCAT2 inhibitors, scientists seek to unravel the complexities of cellular membrane dynamics, lipid homeostasis, and the broader field of cell biology, contributing to our knowledge of how cells maintain the integrity and functionality of their membranes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus inhibits mTOR signaling, which could downregulate LPCAT2 expression as part of a broader effect on lipid metabolism. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
Dactolisib is a dual PI3K/mTOR inhibitor, potentially affecting LPCAT2 expression by altering lipid synthesis pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases and may influence LPCAT2 expression by modulating signal transduction pathways. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine affects lysosomal function, which could indirectly affect LPCAT2 expression by altering cellular lipid processing. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Rosiglitazone is a PPARγ agonist, which might downregulate LPCAT2 expression through effects on lipid metabolism genes. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, potentially affecting LPCAT2 expression by inducing ER stress and the unfolded protein response. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts ER to Golgi transport, which could lead to a reduction in LPCAT2 expression due to stress response pathways. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, which could indirectly affect LPCAT2 expression through cAMP-mediated signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which might influence LPCAT2 expression by modifying stress response signaling. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin can modulate transcription factors and signaling pathways, possibly leading to altered LPCAT2 expression. | ||||||